Bill Humphries, CEO of Alcami, shares his vision for the future, discussing dynamic market trends and the company’s commitment to innovation. Under his leadership, Alcami is poised to redefine the pharmaceutical and biotechnology landscape, focusing on cutting-edge solutions and navigating global complexities. This conversation highlights Alcami’s strategic direction, accomplishments, and upcoming challenges.
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Interview with Olivier Lambrechts, executive leadership team member and president NCE at Arxada.
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?
CDMO Serán BioScience recently announced that it has completed an expansion to increase the number of process manufacturing suites at its facility in Bend, Oregon, from 6 to 14, adding approximately 130% more cGMP clinical manufacturing capacity.
Olon continues its growth path and increases its total production capacity following the acquisition of Huvepharma Italia and its site in Garessio, Cuneo, in the northwestern part of Italy.
Bora Pharmaceuticals, a Taiwan-headquartered contract development and manufacturing organization (CDMO), has completed the acquisition of Emergent BioSolutions' sterile manufacturing facility in Baltimore-Camden, Maryland, USA. The facility adds drug product fill/finish to Bora’s extensive biologics drug substance capabilities.
A recent report by consulting company WittKiefer delves into the role of CDMOs within the pharmaceutical industry, evaluating the effectiveness of existing leadership structures and expertise in navigating market complexities.
Touchlight, a UK-based custom development and manufacturing organization (CDMO) specializing in enzymatic DNA production, signed a license agreement with British drugmaker GSK which grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA (doggybone DNA) technology for the development and production of mRNA-based products.
Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutical and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer.
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.
Navin Molecular, an Indian-headquartered CDMO with small molecule development and manufacturing capabilities, recently announced a Rs 288 Crore (approximately €32.6 million/$35 million) investment to construct a 9,000 m2 GMP manufacturing plant in Dewas, India. The new facility will nearly double the overall capacity at the site to 420 m3. It will support existing commercial-scale projects and meet future demands as the company continues to expand its global customer base.
South Korea-headquartered contract development and manufacturing organization (CDMO) SK Bioscience plans to acquire a 60% stake in IDT Biologika, a German CDMO specialized in vaccines, gene and immune therapy and oncolytic viruses, from Klocke Group. Klocke will retain a 40% stake in IDT Biologika and thus remains the company's second-largest shareholder.
US contract development and manufacturing organization (CDMO) Veranova has initiated an expansion of its antibody-drug conjugate (ADC) and highly potent active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities at its US facility in Devens, Massachusetts.
Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried has signed a binding agreement to acquire an early-phase CDMO site in Grafton, Wisconsin, US, from Curia. The transaction is expected to close by July 1, subject to customary closing conditions.
Siegfried, a global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen, Switzerland, has signed binding agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, Wisconsin, US.
Aurigene Pharmaceutical Services Limited (Aurigene), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 6500 m2 (70,000 sq ft) in Hyderabad, India.
UK-headquartered contract development and manufacturing organization (CDMO) Sterling Pharma Solutions has invested $3 million at its US facility in Germantown, WI, to expand the company’s integrated antibody-drug conjugate (ADC) development and manufacturing capabilities.
Kühne Holding has agreed to purchase Aenova Group, a pharma contract development and manufacturing organization (CDMO), from BC Partners. BC will reinvest and retain a minority stake in Aenova. The financial terms remain undisclosed.
Fujifilm announced an additional investment of $1.2 billion in its large-scale cell culture contract development and manufacturing organization (CDMO) business to further expand the planned Fujifilm Diosynth Biotechnologies facility in Holly Springs, North Carolina, bringing the total investment in the facility to over $3.2 billion. Plans for the new site were unveiled in September last year.
Upperton Pharma Solutions was joined by Sarah Gilbert, Professor and co-creator of the Oxford/AstraZeneca COVID-19 vaccine for the official opening of its new development and GMP manufacturing facility in Nottingham, UK.
Headquartered in Cramlington, UK, Sterling Pharma Solutions is a contract development and manufacturing organization (CDMO) that provides a range of services to the global biopharmaceutical industry, including active pharmaceutical ingredient (API) development, scale-up and cGMP manufacturing, as well as antibody drug conjugate (ADC) R&D and clinical-scale GMP manufacturing.
US biotech company Antheia and Olon, an Italian producer of active pharmaceutical ingredients (APIs), have announced the continuation of their ongoing partnership to utilize Olon’s fermentation infrastructure for the scale-up and commercialization of Antheia’s early products.
Novo Holdings, Novo Nordisk's parent company, is acquiring US contract development and manufacturing organization (CDMO) Catalent for $16.5 billion. The companies said that Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.
Siegfried has appointed Marianne Späne, currently chief business officer Drug Products, as chief business officer with responsibility for both the Drug Substances and Drug Products divisions of the Swiss contract manufacturing and development organization (CDMO), effective Feb. 1, 2024. Christian Dowdeswell, who previously led the Drug Substance business, has decided to leave Siegfried.
Veranova has appointed Chris Holmes as the company’s first vice president, Global Engineering. He will lead Veranova’s global engineering team in the planning, design, and execution of the company’s capital investment initiatives and lead strategic capital projects.
Swiss contract development and manufacturing organization (CDMO) Lonza will collaborate with Oxford Nanopore Technologies, a UK-based company delivering a new generation of nanopore-based molecular sensing technology. The collaboration aims to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA (mRNA).
Active pharmaceutical ingredients manufacturer EuroAPI has started a collaboration with Basel, Switzerland-headquartered SpiroChem, a contract research organization (CRO) which specializes in early chemical process R&D (route scouting).
China-headquartered contract research, development and manufacturing organization (CRDMO) WuXi Biologics plans to increase the manufacturing capacity of its US facility in Worcester, Massachusetts to 36,000 l, 12,000 l more than the originally planned 24,000 l.
CordenPharma and pHLIP have announced their strategic alliance to collaborate in developing and commercializing the pHLIP-LNP targeted delivery platform for RNA-based and genetic therapeutics.
EuroAPI has appointed Ludwig de Mot as chief transformation officer and executive vice president (EVP).
Swiss Biosynth, a supplier of raw materials to the life science industry, has acquired VIO Chemicals, a Zurich, Switzerland-based company with leading chemical R&D expertise and a global network of large-scale manufacturing partners. Financial details of the transaction have not been disclosed.
US API maker Veranova has appointed Lucas Sauer-Jones as the company’s vice president & general manager, New England. He will be responsible for Veranova’s sites in Devens and North Andover.
In the rapidly evolving industry of contract development and manufacturing organizations (CDMOs), a well-defined pricing strategy is essential to drive growth and profitability. To stay ahead and participate in the expansion of the market, CDMOs need to transition to a structured value-based pricing approach that considers customer value, complexity, and specific needs.
